Phase I favorable results for TiGenix’ sepsis drug

June 8, 2015 News BioVox

TiGenix is developing a drug based on allogeneic expanded adipose-derived stem cells (eASCs) to treat artritis and sepsis. The Phase I trials confirmed the safety and tolerability of the drug. The drug was administered via intravenous injection to patients with sepsis, after it showed a favorable safety and tolerability profile in patients with arthritis. The efficacy in significantly reducing mortality has been demonstrated in several animal models of sepsis through a combination of reduced inflammation, production of anti-microbial effectors, and increased phagocytosis.
Investors reacted, enthusiastically resulting in a profit of 1,67% on the stock market.

Avatar photo

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts